Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL
Anna Maria Testi(Sapienza University of Rome), Andrea Pession(University of Bologna), Daniela Diverio(Sapienza University of Rome), David Grimwade(King's College London), Brenda Gibson(Royal Hospital for Children), Amilcar Cardoso de Azevedo(Centro Infantil Boldrini), Lorena Morán(Instituto Argentino de Diagnóstico y Tratamiento), Guy Leverger(Sorbonne Université), Sarah Elitzur(Tel Aviv University), Henrik Hasle(Aarhus University Hospital), Jutte van der Werff ten Bosch(Universitair Ziekenhuis Brussel), Owen Smith(Our Lady's Hospital), Marisa De Rosa(Cineca), Alfonso Piciocchi, Francesco Lo‐Coco(University of Rome Tor Vergata), Robin Foà(Sapienza University of Rome), Franco Locatelli(University of Pavia), Gertjan J.L. Kaspers(Stichting Kinderoncologie Nederland)
Cited by 94Open Access
Abstract
= .043, respectively). These data demonstrate that extended use of ATRA coupled to a risk-adapted consolidation can achieve high cure rates in childhood APL and limit anthracycline exposure. The trial was registered at www.clinicaltrials.gov as EudractCT 2008-002311-40.
Related Papers
No related papers found
Powered by citation graph analysis